Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (NEFOPAIN kinet)

Nefopam is a non-opioid analgesic approved for the symptomatic treatment of acute pain, particularly postoperative pain. The HAS has authorized nefopam tablet, while emphasizing the lack of bibliographic data on both the pharmacokinetic and clinical aspects.

The aim of this study is to evaluate the pharmacokinetics of nefopam tablets.

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Rheumatic Pain
• Intervention / Treatment: Drug: Nefopam administration and prelevment

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Armelle Guidotti; Email: armelle.guidotti@chu-rouen.fr
• Study Contact Backup: Name: Sophie Pouplin, MD; Phone Number: +332 32 88 92 21; Email: sophie.pouplin@chu-rouen.fr

Study Locations

• France
  • Rouen, France
    • CHU de ROUEN
    • Contact: Sophie Pouplin, MD; Phone Number: +332 32 88 92 21; Email: sophie.pouplin@chu-rouen.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient hospitalized in rheumatology,
• Patient presenting with acute pain in the musculoskeletal system,
• Expected remaining length of hospital stay ≥ 4 days,
• EN ≥ 3
• Age ≥ 18 and ≤ 75,
• Patient who has read and understood the information letter and signed the consent form

• Women:

  • Of childbearing age, defined by the CTCG as fertile women, after menarche and until menopause, except in cases of permanent infertility (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)

    • using highly effective contraception according to the CTCG (combined hormonal contraception (estrogen and progesterone) associated with ovulation inhibition (oral, intravaginal, transdermal), hormonal contraception (progesterone only) associated with ovulation inhibition (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence) for at least 4 weeks prior to inclusion, during treatment, and up to 3 days after the last dose/administration of treatment,
    • and having a negative urinary pregnancy test for β-HCG at inclusion.
  • Postmenopausal: Menopause is defined by the CTCG as the absence of menstruation for 12 months without any other medical cause. Elevated follicle-stimulating hormone (FSH) levels in the postmenopausal interval can be used to confirm postmenopausal status in women who are not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
• Patient affiliated with a social security system or beneficiary of such a system.

Exclusion Criteria:

• Patients who have received nefopam within 7 days prior to inclusion
• Patients with creatinine clearance ≤ 30 mL/min according to the CKD-EPI formula
• Severe or uncontrolled cardiovascular disease. Patients treated with enzyme-inducing or enzyme-inhibiting drugs (amiodarone, bupropion, fluoxetine, paroxetine, quinidine, venlafaxine, haloperidol, imipramine, tamoxifen, ketoconazole, ritonavir, clarithromycin, Carbamazepine, St. John's Wort, Itraconazole, Rifampicin, Dexamethasone)
• Patients treated with medication(s) containing alcohol as an excipient.
• Patients with severe hepatic impairment (ASAT and/or ALAT > 5 times the upper normal limit).
• History of psychological or sensory disease or abnormality that may prevent the subject from fully understanding the conditions required for participation in the protocol or prevent them from giving informed consent.
• Patients unable to understand pain scales.

• Medical contraindications for NEFOPAM VIATRIS 20 mg/2 mL, injectable solution, or NEFOPAM PANPHARMA 30 mg, film-coated tablet:

  • Hypersensitivity to nefopam or any of the excipients.
  • Convulsions or history of convulsive disorders.
  • Risk of urinary retention associated with urethroprostatic disorders.
  • Risk of angle-closure glaucoma.
• Patients suffering from constipation.
• Patients with a history of disorders associated with the use of psychoactive substances.
• Pregnant women, women in labor, breastfeeding women, or women who are not using effective contraception.
• Persons deprived of their liberty by administrative or judicial decision or persons placed under judicial protection/guardianship or curatorship

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Sequence 1 : IV then tablet form; administration of Nefopam IV (H0) - washout (H0 à H72) -nefopam tablet administration (H72)	Drug: Nefopam administration and prelevment; Catheter placement, blood samples taken from H0 to H12 after each dose of nefopam in 4mL lithium heparin tubes without separating gel (9 samples per dose of nefopam)
Other: Sequence 2 : tablet then IV form; administration of Nefopam tablet administration (H0) - washout (H0 à H72) -nefopam IV administration (H72)	Drug: Nefopam administration and prelevment; Catheter placement, blood samples taken from H0 to H12 after each dose of nefopam in 4mL lithium heparin tubes without separating gel (9 samples per dose of nefopam)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
terminal elimination half-life	terminal elimination half-life	6 days
Cmax	Peak plasma concentration	6 days
Tmax	time to maximum concentration	6 days
exposure	characterized by the area under the curve obtained using the trapezoidal method	6 days
bioavailability	bioavailability will be calculated using the ratio of AUCs between the oral and intravenous forms	6 days

Collaborators and Investigators

• Sponsor: University Hospital, Rouen

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): April 7, 2027
• Study Completion (Estimated): April 7, 2027

Study Registration Dates

• First Submitted: March 11, 2026
• First Submitted That Met QC Criteria: March 18, 2026
• First Posted (Actual): March 24, 2026

Study Record Updates

• Last Update Posted (Actual): March 24, 2026
• Last Update Submitted That Met QC Criteria: March 18, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 2022/0355/HP; 2025-521926-13-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No